Justin Fontenot, MD
Endocrinology, Diabetes & Metabolism · Lafayette, LANPI 1881790632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $339,235 of the $396,606 with a category attached, or 85.5%. Lilly USA, LLC accounts for 76.8% of it on its own, with 58 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,396 payments — averaging $284.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$304K
- Amgen$37K
- AstraZeneca$33K
- Tandem Diabetes Care, Inc.$14K
- Dexcom, Inc.$2K
- Novo Nordisk$821
- plus $6K from 53 others
Across 3 payments — averaging $169,348 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$419K
- Sanofi$90K
What the payments were for
- Consulting fees$4,2251%
- Speaking & faculty fees$339,23586%
- Travel & lodging$34,4889%
- Food & beverage$18,5765%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$147,184
- TRULICITY$103,668
- FARXIGA$30,965
- TEPEZZA$29,352
- BAQSIMI$26,448
- t-slim insulin pump$7,300
- t:slim X2 insulin pump$5,800
- iLet Bionic Pancreas$634
- DEXCOM G6 TRANSMITTER$247
- iLet Insulin Infusion Kit Inset$211
- iLet Insulin Infusion Kit Contact Detach$211
- INVOKANA$119
- FREESTYLE LIBRE 3$115
- InPen$110
- Ozempic$109
- DEXCOM CGM$101
How this compares
$396,606 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 237 | $285,293 |
| OzempicSemaglutide | 204 | $218,783 |
| JardianceEmpagliflozin | 170 | $148,469 |
| FarxigaDapagliflozin Propanediol | 93 | $95,574 |
| TrulicityDulaglutide | 82 | $90,468 |
| Cinacalcet Hcl | 116 | $75,261 |
| TymlosAbaloparatide | 21 | $63,782 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $57,266 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $45,821 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 35 | $44,444 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $38,840 |
| Teriparatide | 13 | $35,931 |
| SynthroidLevothyroxine Sodium | 476 | $31,037 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $27,458 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 45 | $24,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $304,418 | $378,362340 claims |
| Novo NordiskOzempic, Novolog | $821 | $226,983249 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Trijardy Xr | $279 | $185,021219 claims |
| AstraZenecaFarxiga | $32,504 | $95,57493 claims |
| Radius Health, Inc.Tymlos | $415 | $63,78221 claims |
| AbbVieSynthroid, Armour Thyroid | $77 | $32,739519 claims |
| MerckJanuvia | $207 | $20,70124 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $113 | $10,544966 claims |
| Johnson & JohnsonInvokana | $369 | $7,82812 claims |
| BayerKerendia | $14 | $7,05511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Lafayette
- Bennett BaquetLafayette$30K
- Ghyass RizkLafayette$16K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.